{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:37:43Z","timestamp":1782286663048,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Spasmodic dysphonia (SD) is now generally considered to be a task-specific focal dystonia. For the first time, we wanted to explore the relationship between SD and dystonia from a combined neurological and phoniatric perspective. For this, we studied 115 patients with non-psychogenic SD by a combined neurological and phoniatric evaluation. Onset of SD was 49.7\u2009\u00b1\u200919.0 (6\u201368) years. The female\/male ratio was 2. 63% had additional dystonia manifestations (cervical dystonia 35%, arm dystonia 15%, blepharospasm 11%, oromandibular dystonia 11%, writer\u2019s cramp 11%, pharyngeal dystonia 10%, generalised dystonia 4%, axial dystonia 2%, spasmodic dyspnoea 2% and segmental dystonia 1%). 71% occurred before, 25% after and 4% together with SD. 17% had a family history of dystonia and 6% a history of exposure to dopamine receptor blocking agents. 41% had mixed SD (SD-M), 31% abductor SD (SD-AB) and 28% adductor SD (SD-AD). SD-M was significantly correlated with additional dystonia manifestations and tremulous SD. No patient showed essential tremor or Parkinsonian syndromes. Two third of SD patients have additional dystonia manifestations and one fifth have a family history of dystonia, considerably more than previously described. In half of all patients, SD starts with non-SD dystonia. Our combined approach revealed a high prevalence of SD-M associated with frequent additional dystonia manifestations including dystonic tremor and a family history of dystonia. Patients presenting with SD should be evaluated for additional dystonia manifestations and dystonia patients should be evaluated for SD. Relevant coexistence of essential tremor and Parkinsonian syndromes cannot be confirmed.<\/jats:p>","DOI":"10.1007\/s00702-024-02868-x","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T05:16:32Z","timestamp":1735017392000},"page":"603-608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spasmodic dysphonia: the need for a combined neurological and phoniatric approach"],"prefix":"10.1007","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-3796","authenticated-orcid":false,"given":"Dirk","family":"Dressler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshte","family":"Adib Saberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"2868_CR1","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1136\/jnnp.63.5.688","volume":"63","author":"CH Adler","year":"1997","unstructured":"Adler CH, Bansberg S (1997) Female predominance in spasmodic dysphonia. J Neurol Neurosurg Psychiat 63:688","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"2868_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1044\/jshd.3303.203","volume":"33","author":"AE Aronson","year":"1968","unstructured":"Aronson AE, Brown JR, Litin EM, Pearson JS (1968) Spastic dysphonia. I. Voice, neurologic, and psychiatric aspects. J Speech Hear Disord 33:203\u2013218","journal-title":"J Speech Hear Disord"},{"key":"2868_CR3","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/00005537-199810000-00003","volume":"108","author":"A Blitzer","year":"1998","unstructured":"Blitzer A, Brin MF, Stewart CF (1998) Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 108:1435\u20131441","journal-title":"Laryngoscope"},{"issue":"Suppl 1","key":"2868_CR4","first-page":"S1","volume":"128","author":"B Blitzer","year":"2018","unstructured":"Blitzer B, Brin MF, Simonyan K, Ozelius LJ, Frucht SJ (2018) Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: a 30-year experience. Laryngoscope 128(Suppl 1):S1\u2013S9","journal-title":"Laryngoscope"},{"key":"2868_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/000348947608500205","volume":"85","author":"FS Brodnitz","year":"1976","unstructured":"Brodnitz FS (1976) Spastic dysphonia. Ann Otol Rhinol Laryngol 85:219\u2013231","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2868_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000059525","volume":"21","author":"E Castelon Konkiewitz","year":"2002","unstructured":"Castelon Konkiewitz E, Trender-Gerhard I, Kamm C, Warner T, Ben-Shlomo Y, Gasser T, Conrad B, Ceballos-Baumann AO (2002) Service-based survey of dystonia in munich. Neuroepidemiology 21:202\u2013206","journal-title":"Neuroepidemiology"},{"key":"2868_CR7","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.1007\/s00415-022-11310-9","volume":"269","author":"D Dressler","year":"2022","unstructured":"Dressler D, Altenm\u00fcller E, Giess R, Krauss JK, Adib Saberi F (2022) The epidemiology of dystonia: the Hannover epidemiology study. J Neurol 269:6483\u20136493","journal-title":"J Neurol"},{"key":"2868_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-023-02736-0","author":"D Dressler","year":"2023","unstructured":"Dressler D, Kopp B, Adib PL, Saberi F (2023) The natural course of idiopathic cervical dystonia. J Neural Transm Epub Ahead. https:\/\/doi.org\/10.1007\/s00702-023-02736-0","journal-title":"J Neural Transm Epub Ahead"},{"key":"2868_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0892-1997(01)00038-8","volume":"15","author":"JD Edgar","year":"2001","unstructured":"Edgar JD, Sapienza CM, Bidus K, Ludlow L (2001) Acoustic measures of symptoms in abductor spasmodic dysphonia. J Voice 15:362\u2013372","journal-title":"J Voice"},{"key":"2868_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/toxins13120840","volume":"13","author":"M Hyodo","year":"2021","unstructured":"Hyodo M, Asano K, Nagao A, Hirose K, Nakahira M, Yanagida S, Nishizawa N (2021) Botulinum toxin therapy: a series of clinical studies on patients with spasmodic dysphonia in Japan. Toxins 13:840. https:\/\/doi.org\/10.3390\/toxins13120840","journal-title":"Toxins"},{"key":"2868_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/MOO.0b013e32832aef6f","volume":"17","author":"CL Ludlow","year":"2010","unstructured":"Ludlow CL (2010) Treatment for spasmodic dysphonia: limitations of current approaches. Curr Opin Otolaryngol Head Neck Surg 17:160\u2013165","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"2868_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/mds.870030302","volume":"3","author":"JG Nutt","year":"1988","unstructured":"Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ 3rd (1988) Epidemiology of focal and generalized dystonia in Rochester. Minnesota Mov Disord 3:188\u2013194","journal-title":"Minnesota Mov Disord"},{"key":"2868_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005537-200202000-00004","volume":"112","author":"JM Schweinfurth","year":"2002","unstructured":"Schweinfurth JM, Billante M, Courey MS (2002) Risk factors and demographics in patients with spasmodic dysphonia. Laryngoscope 112:220\u2013223","journal-title":"Laryngoscope"},{"key":"2868_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/jnnp.60.2.204","volume":"60","author":"VL Soland","year":"1996","unstructured":"Soland VL, Bhatia KP, Marsden CD (1996) Sex prevalence of focal dystonias. J Neurol Neurosurg Psychiat 60:204\u2013205","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"2868_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/01.moo.0000145959.50513.5e","volume":"12","author":"L Sulica","year":"2004","unstructured":"Sulica L (2004) Contemporary management of spasmodic dysphonia. Curr Opin Otolaryngol Head Neck Surg 12:543\u2013548","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"2868_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/000348941112000708","volume":"120","author":"K Tanner","year":"2011","unstructured":"Tanner K, Roy N, Merrill RM, Sauder C, Houtz DR, Smith ME (2011) Spasmodic dysphonia: onset, course, socioemotional effects, and treatment response. Ann Otol Rhinol Laryngol 120:465\u2013473","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2868_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/ene.12151","volume":"21","author":"U Walter","year":"2014","unstructured":"Walter U, Blitzer A, Benecke R, Grossmann A, Dressler D (2014) Sonographic detection of basal ganglia abnormalities in spasmodic dysphonia. Eur J Neurol 21:349\u2013352","journal-title":"Eur J Neurol"},{"key":"2868_CR18","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/lary.21872","volume":"121","author":"LJ White","year":"2011","unstructured":"White LJ, Klein AM, Hapner ER, Delgaudio JM, Hanfelt JJ, Jinnah HA, Johns MM 3rd (2011) Coprevalence of tremor with spasmodic dysphonia: a case-control study. Laryngoscope 121:1752\u20132175","journal-title":"Laryngoscope"},{"key":"2868_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/BF00874096","volume":"254","author":"P Zwirner","year":"1997","unstructured":"Zwirner P, Dressler D, Kruse E (1997) Spasmodic laryngeal dyspnea: a rare manifestation of laryngeal dystonia. Eur Arch Otorhinolaryngol 254:242\u2013245","journal-title":"Eur Arch Otorhinolaryngol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-024-02868-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-024-02868-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-024-02868-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:14:28Z","timestamp":1741965268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-024-02868-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2868"],"URL":"https:\/\/doi.org\/10.1007\/s00702-024-02868-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DD received honoraria for services provided to Allergan, Ipsen, Merz, Lanzhou Institute of Biological Products, Medy-Tox, Revance, Desitin, Syntaxin, AbbVie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, WizMedi, IAB-Interdisciplinary Working Group for Movement Disorders. He is shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. FAS is founder and owner of IAB\u2014Interdisciplinary Working Group for Movement Disorders. She received reimbursement from Abbot, AbbVie, Almirall, Allergan, Bayer, Desitin, Dynamed, Hempel GesundheitsPartner, Ipsen, Johnson & Johnson, Licher, Meda, Medtronic, Merz, Orion, PTZ Nawrath, Sensomotorik & Rehabilitation Hellmuth & Thiel, Sintetica, Sporlastic, Sun, Teva, Tricumed, TRS Med, UCB. LP and BK have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}